Maze Therapeutics
Update in progressMAZE (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Maze Therapeutics is a clinical-stage biopharmaceutical company in South San Francisco that develops small-molecule precision medicines for kidney and metabolic diseases. Its lead programs include MZE829, an oral APOL1 inhibitor in Phase II for APOL1-associated kidney disease; MZE782, an oral inhibitor for phenylketonuria and chronic kidney disease in Phase II-ready trials; and MZE001 for Pompe disease. It collaborates with Trace Neuroscience, Shionogi, and Neurocrine Biosciences.
Company score
- Sentiment
- 0.29
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.18
- Governance
- -0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.16
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Jason V. Coloma M.B.A., M.P.H., Ph.D.
- Founded2017
- Employees141
- Websitewww.mazetx.com
Identifiers
- ISINUS5787841007
- FIGIBBG00NHJHS27